Exelixis, Inc. (EXEL) analyst actions
Rating and price-target actions on EXEL in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the EXEL overview →
5 measured EXEL analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Exelixis, Inc. (EXEL) And Encourages Shareholders to Reach Out | Press release | +0.18% | -0.68% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Exelixis, Inc. (EXEL) And Encourages Stockholders to Reach Out | Press release | -0.08% | -0.92% | |
| Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors | Press release | +5.83% | +9.84% | |
| Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors | Press release | -0.32% | +0.27% | |
| Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer | Press release | +1.28% | +2.70% |
Keep exploring
More EXEL: earnings → · SEC filings → · EXEL overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Eagle Pharmaceuticals, Inc. (EGRX) | 555 | 0.00% | 44% |
| Titan Medical Inc. - Ordinary Shares (TMDI) | 552 | -0.06% | 43% |
| ACHAOGEN (AKAO) | 547 | -0.26% | 44% |
| FIBROCELL SCIENCE INC COMMON (FCSC) | 547 | -0.17% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.